159 related articles for article (PubMed ID: 32777298)
61. Physicians' opinions following pharmacogenetic testing for psychotropic medication.
Walden LM; Brandl EJ; Changasi A; Sturgess JE; Soibel A; Notario JF; Cheema S; Braganza N; Marshe VS; Freeman N; Tiwari AK; Kennedy JL; Müller DJ
Psychiatry Res; 2015 Oct; 229(3):913-8. PubMed ID: 26298505
[TBL] [Abstract][Full Text] [Related]
62. Pharmacogenetic Testing: Why Is It So Disappointing?
Limandri BJ
J Psychosoc Nurs Ment Health Serv; 2019 Apr; 57(4):9-12. PubMed ID: 30933297
[TBL] [Abstract][Full Text] [Related]
63. Pharmacogenomics-based practice in North Cyprus: its adoption by pharmacists and their attitudes and knowledge.
Alsaloumi L; Abdi A; Tosun Ö; Başgut B
Int J Clin Pharm; 2019 Oct; 41(5):1299-1306. PubMed ID: 31267362
[TBL] [Abstract][Full Text] [Related]
64. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing.
Roederer MW; Van Riper M; Valgus J; Knafl G; McLeod H
Per Med; 2012 Jan; 9(1):19-27. PubMed ID: 29783293
[TBL] [Abstract][Full Text] [Related]
65. Implementation of inpatient models of pharmacogenetics programs.
Cavallari LH; Lee CR; Duarte JD; Nutescu EA; Weitzel KW; Stouffer GA; Johnson JA
Am J Health Syst Pharm; 2016 Dec; 73(23):1944-1954. PubMed ID: 27864202
[TBL] [Abstract][Full Text] [Related]
66. An evaluation of pharmacists' expectations towards pharmacogenomics.
de Denus S; Letarte N; Hurlimann T; Lambert JP; Lavoie A; Robb L; Sheehan NL; Turgeon J; Vadnais B
Pharmacogenomics; 2013 Jan; 14(2):165-75. PubMed ID: 23327577
[TBL] [Abstract][Full Text] [Related]
67. Pharmacogenetics: from bench to byte.
Swen JJ; Wilting I; de Goede AL; Grandia L; Mulder H; Touw DJ; de Boer A; Conemans JM; Egberts TC; Klungel OH; Koopmans R; van der Weide J; Wilffert B; Guchelaar HJ; Deneer VH
Clin Pharmacol Ther; 2008 May; 83(5):781-7. PubMed ID: 18253145
[TBL] [Abstract][Full Text] [Related]
68. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel.
Bousman C; Maruf AA; Müller DJ
Curr Opin Psychiatry; 2019 Jan; 32(1):7-15. PubMed ID: 30299306
[TBL] [Abstract][Full Text] [Related]
69. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
Bashir NS; Ungar WJ
Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
[TBL] [Abstract][Full Text] [Related]
70. Acceptance and attitudes of healthcare staff towards the introduction of clinical pharmacy service: a descriptive cross-sectional study from a tertiary care hospital in Sri Lanka.
Shanika LG; Wijekoon CN; Jayamanne S; Coombes J; Coombes I; Mamunuwa N; Dawson AH; De Silva HA
BMC Health Serv Res; 2017 Jan; 17(1):46. PubMed ID: 28100204
[TBL] [Abstract][Full Text] [Related]
71. Potential roles for pharmacists in pharmacogenetics.
El-Ibiary SY; Cheng C; Alldredge B
J Am Pharm Assoc (2003); 2008; 48(2):e21-e32. PubMed ID: 18359724
[TBL] [Abstract][Full Text] [Related]
72. Pharmacogenomics: bridging the gap between science and practice.
Lee KC; Ma JD; Kuo GM
J Am Pharm Assoc (2003); 2010; 50(1):e1-14; quiz e15-7. PubMed ID: 20368146
[TBL] [Abstract][Full Text] [Related]
73. Moving Pharmacogenetics Into Practice: It's All About the Evidence!
Luzum JA; Petry N; Taylor AK; Van Driest SL; Dunnenberger HM; Cavallari LH
Clin Pharmacol Ther; 2021 Sep; 110(3):649-661. PubMed ID: 34101169
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of prescriber responses to pharmacogenomics clinical decision support for thiopurine
Ubanyionwu S; Formea CM; Anderson B; Wix K; Dierkhising R; Caraballo PJ
Am J Health Syst Pharm; 2018 Feb; 75(4):191-198. PubMed ID: 29436466
[TBL] [Abstract][Full Text] [Related]
75. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
[TBL] [Abstract][Full Text] [Related]
76. The extraction of pharmacogenetic and pharmacogenomic relations--a case study using PharmGKB.
Buyko E; Beisswanger E; Hahn U
Pac Symp Biocomput; 2012; ():376-87. PubMed ID: 22174293
[TBL] [Abstract][Full Text] [Related]
77. Crunch time for multiple-gene tests.
Gewin V
Nature; 2007 Jan; 445(7126):354-5. PubMed ID: 17251949
[No Abstract] [Full Text] [Related]
78. International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.
Pereira NL; So D; Bae JH; Chavez I; Jeong MH; Kim SW; Madan M; Graham J; O'Cochlain F; Pauley N; Lennon RJ; Bailey K; Hasan A; Baudhuin LM; Bell MR; Lerman A; Goodman S; Mathew V; Farkouh M; Rihal CS
Pharmacogenet Genomics; 2019 Jun; 29(4):76-83. PubMed ID: 30724853
[TBL] [Abstract][Full Text] [Related]
79. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.
Jaquenoud Sirot E; van der Velden JW; Rentsch K; Eap CB; Baumann P
Drug Saf; 2006; 29(9):735-68. PubMed ID: 16944962
[TBL] [Abstract][Full Text] [Related]
80. Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System.
Olander M; Waring S; Stenehjem DD; Taran A; Ranelli P; Brown JT
Innov Pharm; 2018; 9(2):1-12. PubMed ID: 34007697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
